Despite the disadvantage of low sensitivity, low specificity and limited accuracy in HCC early diagnosis, AFP has still been recommended as a serum biomarker for diagnosis of HCC in clinical practice in China, which accounts for more than 55% of annually diagnosed HCC patients. Here, AFP is linked to hepatocellular carcinoma.